Akshta Pai is a Nephrology physician. OpenAlex indexes 11 publications with 328 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
622 W 168th St
New York, NY 100323720
Telephone
212-342-5155Registry record last updated 24 May 2016.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Aurinia Pharma U.S., Inc.Program year20251 payment
- Veloxis Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
42.6%Beta blocker13.5%Carvedilol100%Part D≥13 patientsCalcium channel blocker8.4%Nifedipine Er100%Part D≥11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
38.1%Corticosteroid25.8%Prednisone100%Part D≥19 patientsProton pump inhibitor7.4%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
12.6%Calcium-sensing Receptor Agonist12.6%Cinacalcet Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Trends in Kidney Allograft Failure Among First-Time Transplant Recipients in the United States
American Journal of Kidney Diseases
2024 - TCT-143 A Validated Risk Model for Acute Kidney Injury Prediction in Patients Undergoing Transcatheter Aortic Valve Replacement Insights From the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry: Transcatheter Valve Therapy Registry
Journal of the American College of Cardiology
2024 - Measurement of Fatigue in Patients Receiving Kidney Replacement Therapy
American Journal of Kidney Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”